5.24
price down icon8.23%   -0.47
pre-market  Vorhandelsmarkt:  5.47   0.23   +4.39%
loading
Schlusskurs vom Vortag:
$5.71
Offen:
$5.66
24-Stunden-Volumen:
5.51M
Relative Volume:
2.14
Marktkapitalisierung:
$466.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-6.93%
1M Leistung:
+0.38%
6M Leistung:
+49.71%
1J Leistung:
+181.72%
1-Tages-Spanne:
Value
$5.15
$5.66
1-Wochen-Bereich:
Value
$5.15
$6.44
52-Wochen-Spanne:
Value
$1.67
$6.44

Atyr Pharma Inc Stock (ATYR) Company Profile

Name
Firmenname
Atyr Pharma Inc
Name
Telefon
(858) 731-8389
Name
Adresse
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Name
Mitarbeiter
59
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
ATYR's Discussions on Twitter

Vergleichen Sie ATYR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ATYR
Atyr Pharma Inc
5.24 501.09M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-18 Eingeleitet Leerink Partners Outperform
2025-01-06 Eingeleitet Cantor Fitzgerald Overweight
2024-10-04 Eingeleitet Wells Fargo Overweight
2024-09-05 Eingeleitet Jefferies Buy
2023-07-05 Herabstufung Oppenheimer Outperform → Perform
2021-10-12 Eingeleitet RBC Capital Mkts Outperform
2021-09-21 Eingeleitet Piper Sandler Overweight
2021-05-10 Eingeleitet Laidlaw Buy
2020-08-17 Hochstufung H.C. Wainwright Neutral → Buy
2020-03-04 Eingeleitet ROTH Capital Buy
2020-03-02 Eingeleitet Oppenheimer Outperform
2018-02-14 Herabstufung JP Morgan Neutral → Underweight
2017-09-07 Eingeleitet Piper Jaffray Overweight
2016-12-13 Herabstufung JP Morgan Overweight → Neutral
2015-12-16 Eingeleitet Citigroup Neutral
2015-06-01 Eingeleitet Citigroup Buy
2015-06-01 Eingeleitet JP Morgan Overweight
Alle ansehen

Atyr Pharma Inc Aktie (ATYR) Neueste Nachrichten

pulisher
Jul 22, 2025

What drives aTyr Pharma Inc. stock priceMarket-beating returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

aTyr Pharma Inc. Stock Analysis and ForecastFree Risk Assessment Services - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about aTyr Pharma Inc. stockExponential return rates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is aTyr Pharma Inc. a good long term investmentUnmatched profit growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

aTyr Pharma Announces Last Patient Visit in Phase 3 - GlobeNewswire

Jul 22, 2025
pulisher
Jul 19, 2025

aTyr Pharma Reaches US$515m Market Cap Benefiting Insider Stock Buying - simplywall.st

Jul 19, 2025
pulisher
Jul 18, 2025

aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Jul 18, 2025
pulisher
Jul 18, 2025

RNA Therapeutics and RNA Vaccines Market Industry Report 2025-2035: Investments in RNA Technologies Surge with USD 2.9 Billion Funding - GlobeNewswire Inc.

Jul 18, 2025
pulisher
Jul 16, 2025

What makes aTyr Pharma Inc. stock price move sharplyFree Stock Trading Community - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

How aTyr Pharma Inc. stock performs during market volatilityTop Growth Low Risk Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why aTyr Pharma Inc. stock attracts strong analyst attentionProven Win Setups - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Can ATyr's EFZO-FIT Data Help Patients And Investors Breathe Easier? - RTTNews

Jul 14, 2025
pulisher
Jul 11, 2025

Pulmonary Sarcoidosis Market on Track for Major Expansion - openPR.com

Jul 11, 2025
pulisher
Jul 11, 2025

Pulmonary Sarcoidosis Market on Track for Major Expansion by 2032, According to DelveInsight | aTyr Pharma, Kinevant Sciences, Novartis, aTyr Pharma, Novartis Pharma, Mallinckrodt - Barchart.com

Jul 11, 2025
pulisher
Jul 07, 2025

Favourable Signals For aTyr Pharma: Numerous Insiders Acquired Stock - Yahoo Finance

Jul 07, 2025
pulisher
Jul 07, 2025

aTyr Pharma: Insider Buys and Russell 2000 Inclusion Signal a Rare Buying Opportunity - AInvest

Jul 07, 2025
pulisher
Jul 06, 2025

Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying - MSN

Jul 06, 2025
pulisher
Jun 30, 2025

ATyr Pharma, Inc.(NasdaqCM: ATYR) added to Russell Small Cap Comp Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 29, 2025

ATyr Pharma, Inc.(NasdaqCM: ATYR) added to Russell 3000E Value Index - MarketScreener

Jun 29, 2025
pulisher
Jun 27, 2025

Leerink Partners Sticks to Its Buy Rating for aTyr Pharma (ATYR) - The Globe and Mail

Jun 27, 2025
pulisher
Jun 26, 2025

aTyr Pharma to join Russell 2000 and 3000 indexes By Investing.com - Investing.com India

Jun 26, 2025
pulisher
Jun 26, 2025

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes - GlobeNewswire

Jun 26, 2025
pulisher
Jun 26, 2025

Clinical-Stage Biotech aTyr Pharma Secures Dual Russell Index Addition, Expanding Market Presence - Stock Titan

Jun 26, 2025
pulisher
Jun 25, 2025

Is aTyr Pharma, Inc. technically bullish or bearish? - MarketsMojo

Jun 25, 2025
pulisher
Jun 24, 2025

Kingswood Wealth Advisors LLC Sells 10,000 Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) - Defense World

Jun 24, 2025
pulisher
Jun 20, 2025

aTyr Pharma (ATYR) Sees Price Target Raised Amid Optimism for Ph - GuruFocus

Jun 20, 2025
pulisher
Jun 20, 2025

Wells Fargo Maintains ATyr Pharma(ATYR.US) With Buy Rating, Raises Target Price to $25 - 富途牛牛

Jun 20, 2025
pulisher
Jun 17, 2025

With 70% ownership, aTyr Pharma, Inc. (NASDAQ:ATYR) boasts of strong institutional backing - Yahoo Finance

Jun 17, 2025
pulisher
Jun 16, 2025

Bank of America Corp DE Makes New $330,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat

Jun 16, 2025
pulisher
Jun 14, 2025

Cantor Fitzgerald Comments on Atyr PHARMA FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Two Sigma Investments LP Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World

Jun 14, 2025
pulisher
Jun 14, 2025

91,224 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Bank of America Corp DE - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

Atyr PHARMA (NASDAQ:ATYR) Stock Price Up 6.1%Here's Why - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Estimates Atyr PHARMA FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

aTyr: Promising Data But Cash May Be An Issue (NASDAQ:ATYR) - Seeking Alpha

Jun 10, 2025

Finanzdaten der Atyr Pharma Inc-Aktie (ATYR)

Es liegen keine Finanzdaten für Atyr Pharma Inc (ATYR) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Atyr Pharma Inc-Aktie (ATYR) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Broadfoot Jill Marie
Chief Financial Officer
Feb 04 '25
Sale
3.78
1,254
4,740
31,763
DENYES NANCY
General Counsel
Feb 04 '25
Sale
3.78
899
3,398
26,555
SCHIMMEL PAUL
Director
Jul 24 '24
Buy
1.93
52,300
101,038
413,023
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):